Replies to post #349514 on Amarin Corp Plc (AMRN)

[MNBioMike]

Agreed, but that is a different set of facts. Look, the GSK/Teva case is a nice incremental move and an important shift, but certainly doesn't 100% seal things up.

Does it shift the risk/reward for generics with respect to Vascepa, which is expensive and difficult to mfg? I certainly think yes.